Hope you do well with it Bubba, but I think you're about 3 years late:
The information about the company was announced on 30th April 2002:
PrionSense Ltd.
The company develops diagnostics and therapeutics for people and animals with Prion diseases. Prions are responsible for Mad Cow Disease in animals and Creutzfeldt-Jakob disease in humans.
In 2001, Priosense Ltd. was founded by Hadasit together with Dr. Ruth Gabizon of Hadassah's Department of Neurology and her research team. The company is committed to the research, development and marketing of innovative diagnostic and therapeutic products for the control and treatment of neurodegenerative diseases.
PrioSense's proprietary technology is based on Dr. Gabizon's biotechnological research. Her core breakthrough was the early identification of the Prion diseases: Bovine Spongiform Encephalopathy (BSE) or "Mad Cow Disease"; Scrapie and variant Creutzfeldt- Jakob Disease (vCJD); through the detection of PrPSc in peripheral tissues.
The company's underlying technology represents a dramatic change in the diagnosis of BSE and vCJD. It introduced a shift from an expensive and cumbersome biopsy-based diagnosis to a simple Elisa-based in-vitro test that allows for mass screening and early diagnosis before the appearance of the clinical symptoms.
Priosense has already developed immunological methods for identifying PrPSc in urine, using commercially available antibodies. This technology was tested on hamsters, humans and cattle. PrioSense intends to utilize this innovative technology to develop a range of products and commercialize them by implementing a unique business model and forming strategic alliances with large veterinary and pharmaceutical companies.
The company also intends to use its proprietary technology and scientific capabilities to develop additional diagnostic tests and innovative target drugs for other neurodegenerative diseases, such as Alzheimer's disease.
PrioSense, will be launched under the auspices of Hadassit, Hadassah’s research and development arm. It will bring to the market a highly accurate commercial diagnostic kit for BSE, based on the work of the Experimental Neurology Laboratory team at the Hadassah–Hebrew University Medical Center at Ein Karem.
"We are very excited about the new range of applications for prion testing, particularly in the field of human medicine", says Dr. Bruno Oesch, CEO and Head of Research at Prionics. "For years we thought that live tests might not be possible based on the direct detection of prion proteins in body fluids, but might require testing of less reliable third markers. The prion protein correlates 100% with disease and therefore facilitates the highest accuracy in diagnosis of BSE and CJD."
"We are delighted to formally partner with Prionics," said Dr. Raphael Hofstein, managing Director of Hadasit and Director at PrioSense. "It is an honour to work with a company that is internationally recognised for its competence in prion diagnostics as well as for its technological and marketing skills."
--------------------------------------------------------------------------------